Down syndrome cells edited

Down syndrome happens when cells carry a third copy of chromosome 21, and a 2025 lab study showed CRISPR-Cas9 can remove that extra chromosome in some human cell models. (academic.oup.com, nichd.nih.gov) The paper, published February 18, 2025 in *PNAS Nexus*, came from researchers at Mie University and collaborators in Japan, not Hiroshima University. The team reported “trisomic rescue” in human trisomy 21 induced pluripotent stem cells and fibroblasts. (academic.oup.com, pubmed.ncbi.nlm.nih.gov) Induced pluripotent stem cells are adult cells reprogrammed back into a flexible, early-state cell that scientists use as a disease model. In this study, the researchers used an allele-specific CRISPR approach, meaning they aimed their cuts at sequence differences unique to the extra chromosome 21 copy. (nigms.nih.gov, academic.oup.com) CRISPR is often described as molecular scissors, but here the goal was not a small edit inside one gene. The researchers made multiple cuts across the targeted chromosome so the cell would lose the entire extra copy, returning from three copies of chromosome 21 to two. (pmc.ncbi.nlm.nih.gov, academic.oup.com) The authors reported that temporary knockdown of DNA repair genes increased chromosome-loss rates, and that corrected cells showed reversed gene-signature changes and improved cellular phenotypes. The abstract also says the strategy worked in differentiated, nondividing cells as well as in induced pluripotent stem cells and fibroblasts. (academic.oup.com) That result does not mean Down syndrome was treated in a person. The work was done in cells in the lab, and the authors said off-target cutting, chromosome-breaking damage, delivery, and translation to medical use still need to be solved. (academic.oup.com, pmc.ncbi.nlm.nih.gov) This line of research has been building for years. A 2017 *Genome Biology* paper showed CRISPR/Cas9-mediated targeted chromosome elimination could remove chromosome 21 in human induced pluripotent stem cells with trisomy 21, and a 2022 Hiroshima University report described spontaneous chromosome correction during iPS cell reprogramming rather than CRISPR removal. (pmc.ncbi.nlm.nih.gov, hiroshima-u.ac.jp) A separate April 2026 report described another lab strategy: using a modified CRISPR system to insert XIST, a natural chromosome-silencing mechanism, into the extra chromosome 21 in Down syndrome cells. That approach aimed to switch the chromosome off rather than physically remove it. (reuters.com, medicalxpress.com) The science is moving alongside a live ethics debate because Down syndrome is a genetic condition tied to disability, identity, prenatal screening, and reproductive decision-making. The National Down Syndrome Society says trisomy 21 accounts for about 95% of cases, while mosaic Down syndrome accounts for a small minority, underscoring that not every case has the same cellular pattern. (ndss.org, cdc.gov) So the cleanest way to describe the news is narrower than many viral posts: scientists have shown in human cell models that one extra chromosome 21 can sometimes be removed or silenced in the lab. No patient therapy has been shown yet, and the field is still at the proof-of-concept stage. (academic.oup.com, reuters.com)